A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab

  • Kefford, Richard (Primary Chief Investigator)
  • Cunningham, Jacob (Research Assistant)

Project: Other

Project Details

Effective start/end date6/03/195/11/20